This report provides information on the therapeutic development for Heart Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Heart Transplantation. Heart Transplantation – Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope of the report “Heart Transplantation – Pipeline Review, H1 2013” (http://www.reportsnreports.com/reports/249492-heart-transplantation-pipeline-review-h1-2013.html) covers:
– A snapshot of the global therapeutic scenario for Heart Transplantation.
– A review of the Heart Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
– Coverage of products based on various stages of development ranging from discovery till registration stages.
– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
– Coverage of the Heart Transplantation pipeline on the basis of route of administration and molecule type.
– Key discontinued pipeline projects.
– Latest news and deals relating to the products.
Companies Involved in Heart Transplantation Therapeutics Development Covered in this report include: Novartis AG, Astellas Pharma Inc., Alexion Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc., NasVax Ltd. and ToleroTech Inc.
Drug Profiles covered in this report: TT-32, Zortress, Anti-aCD3 Mab, JAK3 Specific Inhibitors, AS-2521780 and siRejection.
List of Tables in the report:
Number of Products Under Development for Heart Transplantation, H1 2013 7
Products under Development for Heart Transplantation – Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 11
Products under Development by Companies, H1 2013 12
Novartis AG, H1 2013 13
Astellas Pharma Inc., H1 2013 14
Alexion Pharmaceuticals, Inc., H1 2013 15
Portola Pharmaceuticals, Inc., H1 2013 16
NasVax Ltd., H1 2013 17
ToleroTech Inc., H1 2013 18
Assessment by Monotherapy Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 23
Heart Transplantation Therapeutics – Drug Profile Updates 31
Heart Transplantation Therapeutics – Dormant Products 33
List of Figures in the report:
Number of Products under Development for Heart Transplantation, H1 2013 7
Products under Development for Heart Transplantation – Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Pre-Clinical Stage Products, H1 2013 11
Assessment by Monotherapy Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 23
Contact [email protected] for further information.
List of Tables
Number of Products Under Development for Heart Transplantation, H1 2013 7
Products under Development for Heart Transplantation – Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 11
Products under Development by Companies, H1 2013 12
Novartis AG, H1 2013 13
Astellas Pharma Inc., H1 2013 14
Alexion Pharmaceuticals, Inc., H1 2013 15
Portola Pharmaceuticals, Inc., H1 2013 16
NasVax Ltd., H1 2013 17
ToleroTech Inc., H1 2013 18
Assessment by Monotherapy Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 23
Heart Transplantation Therapeutics – Drug Profile Updates 31
Heart Transplantation Therapeutics – Dormant Products 33
List of Figures
Number of Products under Development for Heart Transplantation, H1 2013 7
Products under Development for Heart Transplantation – Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Pre-Clinical Stage Products, H1 2013 11
Assessment by Monotherapy Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 23